Product Information
METHIMAZOLE 5 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.0702 per EA under NDC 64980026401. Its NADAC has been published 178 times since May 10, 2023.
FDA first approved this application on Mar 7, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
64980026401
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METHIMAZOLEApproval Type
Generic (ANDA)
FDA Application
ANDA202068FDA Approved
3/7/2012
TE Code
AB
On Market Since
4/22/2021
Pharmacological Classes
Price Statistics
The NADAC for METHIMAZOLE 5 MG TABLET has been published 178 times since May 10, 2023, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0702 per EA |
|---|---|
| All-time high | $0.1140 (Sep 13, 2023) |
| All-time low | $0.0661 (Nov 20, 2024) |
| 52-week high | $0.0861 |
| 52-week low | $0.0702 |
| Median price | $0.0788 |
| Average price | $0.0806 |
| Largest weekly change | +27.3% (Aug 23, 2023) |
| Weeks tracked | 178 |
| Tracking since | May 10, 2023 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
methimazole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Thyroid Hormone Synthesis Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METHIMAZOLE 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for METHIMAZOLE 5 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $0.0702 per EA (NDC 64980026401), effective Sep 30, 2026.
How has the price of METHIMAZOLE 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for METHIMAZOLE 5 MG TABLET has held within roughly two percent of its current level. It has been tracked across 178 weekly CMS publications since May 10, 2023.
What are the highest and lowest recorded NADAC prices for METHIMAZOLE 5 MG TABLET?
Since May 10, 2023, the NADAC for METHIMAZOLE 5 MG TABLET has ranged from a low of $0.0661 (Nov 20, 2024) to a high of $0.1140 (Sep 13, 2023), with a median of $0.0788 per EA.
Are there cheaper alternatives to METHIMAZOLE 5 MG TABLET?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as METHIMAZOLE 5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures METHIMAZOLE 5 MG TABLET?
METHIMAZOLE 5 MG TABLET (NDC 64980026401) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.